GlassScriptPhysician profile
Robert Fernandez
NPI 1265755417
$3,521.57
in general payments reported to CMS, 2019-2025
31 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $125 · 2021: $75.52 · 2022: $726 · 2023: $545 · 2024: $696 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $688.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $276.67 | 2019-2025 | |
| Novo Nordisk INC | $222.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $218.96 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $202.37 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $171.31 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $142.96 | 2024-2025 | Winrevair, Vaxneuvance, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $117.37 | 2022-2025 | Trintellix |
| Dexcom, INC. | $79.22 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $70.22 | 2019-2023 | Farxiga |
| Harmony Biosciences LLC | $59.02 | 2024 | |
| Sanofi Pasteur INC. | $56.47 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $44.01 | 2021-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $43.44 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $41.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $37.25 | 2023 | Quviviq |
| Boston Scientific Corporation | $36.66 | 2019 | |
| Edwards Lifesciences Corporation | $36.04 | 2025 | Sapien 3 Ultra Resilia |
| Therapeuticsmd, INC. | $34.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.08 | 2020-2022 | |
| Lundbeck LLC | $26.19 | 2023 | Rexulti |
| Abiomed | $24.19 | 2024 | Impella |
| Viatris Specialty LLC | $21.96 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $21.81 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $21.32 | 2022 | |
| Insmed, INC. | $19.22 | 2025 | Arikayce |
| Phathom Pharmaceuticals, INC. | $18.66 | 2024 | Voquezna |
| Evofem Biosciences, INC. | $17.77 | 2022 | |
| Allergan, INC. | $17.23 | 2019 | |
| Coopersurgical, INC. | $13.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.